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Abstract: Optimizing processing conditions to achieve a critical quality attribute (CQA) is an integral
part of pharmaceutical quality by design (QbD). It identifies combinations of material and processing
parameters ensuring that processing conditions achieve a targeted CQA. Optimum processing
conditions are formulation and equipment-dependent. Therefore, it is challenging to translate a
process design between formulations, pilot-scale and production-scale equipment. In this study, an
empirical model was developed to determine optimum processing conditions for direct compression
formulations with varying flow properties, across pilot- and production-scale tablet presses. The
CQA of interest was tablet weight variability, expressed as percentage relative standard deviation.
An experimental design was executed for three model placebo blends with varying flow properties.
These blends were compacted on one pilot-scale and two production-scale presses. The process model
developed enabled the optimization of processing parameters for each formulation, on each press,
with respect to a target tablet weight variability of <1%RSD. The model developed was successfully
validated using data for additional placebo and active formulations. Validation formulations were
benchmarked to formulations used for model development, employing permeability index values to
indicate blend flow.
Keywords: quality by design; tablet weight variability; powder flow; process optimization; process
model; direct compression
1. Introduction
Direct compression is a relatively simple method to manufacture pharmaceutical
tablets. It involves two primary processing steps, viz., blending and compaction and
is less complicated compared to tablet production involving a dry granulation or wet
granulation step [1]. The compaction process can be subdivided into die filling, compaction,
decompression and ejection. To produce tablets of sufficient quality at production scale,
direct compression formulations are required to exhibit adequate flow, blend uniformity,
compaction and ease of ejection from the tablet press [1–5].
Formulation flow properties significantly impact on the first stage of compaction,
i.e., die filling. Die filling determines the mass of formulation in the die and hence tablet
weight. For uniform blends, the drug dose per tablet is determined during the die filling
step. Non-uniform die filling can result in variable tablet density/porosity, hardness/tensile
strength, disintegration and dissolution [6–11]. To facilitate uniform die filling, rotary tablet
press designs incorporate a forced feeder, or feed frame. The design of the feed frame varies
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between tablet press models [9]. Commercial tablet processes aim to maximise the tablet
production rate while maintaining compliance with product specifications. The relationship
between press speed, feed frame design and speed, and formulation flow properties
influences the die filling process and hence the quality of the tablets produced [9,12].
The regulatory guidance regarding the application of Quality by Design (QbD) during
the design and development of pharmaceutical processes, ICH Q8 (R2), was introduced
more than 10 years ago [13]. Process understanding and optimisation are integral to
QbD. The establishment of optimum processing conditions for direct compression tablet
formulations is widely reported [14–21]. The majority of these studies were completed
using laboratory- or pilot-scale tablet presses with a limited number at commercial scale [20].
It is worth noting that for multi-stage processes such as direct compression, the process
can be broken down into a series of process optimizations for various stages: filling,
compaction and ejection. For example, optimum process conditions developed for the die
filling stage of a direct compression process would identify tablet weight and tablet weight
variability as critical quality attributes and investigate material attributes, such as blend
density and flow, and processing parameters, such as press speed and feed frame speed,
to determine optimum processing parameters [6,9,22,23]. For any formulation, a tablet’s
weight uniformity depends on the uniformity of the die cavity fill. The efficiency of the
die filling process is influenced by powder blend properties such as flowability, cohesion,
particle size, morphology, as well as process parameters such as die table and feed frame
speed [24].
The optimum process parameters are commonly established during the development
stage using pilot-scale tablet presses due to limited access to production equipment and
the quantities of drug required at early stages of development [25,26]. However, due to
differences in equipment models/designs utilised at pilot scale and at production scale,
extrapolation of process understanding from pilot to production scale is challenging, as this
may be scale- and equipment-dependent. To employ the process conditions at commercial
scale that are developed at pilot scale, a justification is required: geometric considerations,
kinematic considerations, heat and mass transfer, or dimensionless numbers [27]. It is
challenging to generate a single optimum processing condition that will encompass both
pilot- and production-scale equipment. This is particularly evident for tablet presses where
feeder designs and press speeds can vary greatly between tablet presses from different
manufacturers [28].
Additionally, achieving optimal processing parameters can be formulation-dependent,
and the transfer of learnings between formulations is challenging. The ability to predict
the performance of formulations and establish optimum processing conditions on different
production press models is advantageous. It reduces costly experimentation during scale-
up, reduces the risk of failure on scale-up and transfer between equipment trains and
enables flexibility in production schedules. However, due to differences in press designs
and control strategies, it is challenging to transfer a formulation between production
presses. Each process optimization generated is to some degree limited by the equipment
on which the experimental runs were conducted and the formulation processed.
The study presented details the development of an empirical process model for the die
fill filling step which describes the tablet weight variability of three placebo formulations,
with different flow characteristics, on three different tablet presses. The tablet presses used
to establish the process model included one pilot-scale and two production-scale presses.
The model developed in this work established the optimum processing parameters of
each formulation on each press with respect to tablet weight variability. The model was
successfully validated by retrospectively predicting the behaviour of an additional placebo
and API formulation on the production-scale tablet presses.
The aim of the study is not to compare the capability of different tablet press designs
at comparable process settings. The study was designed to evaluate the tablet weight
variability for blends with a range of flow properties on tablet presses equipped with their
standard feeder systems and employing control strategies routinely using in commercial
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production. The benefit of such an applied approach is that it can inform the manufacturer
on how formulations will behave in practice during transfer between presses and scale-up
from pilot level to production level.
2. Materials and Methods
2.1. Formulation Design
The three placebo formulations used in the development of the process model were
designed to exhibit good, fair and passable flow. Carr’s compressibility index [29], Hausner
ratio [29,30], angle of repose and permeability index (detailed in Section 2.3) were deter-
mined for the three formulations as markers of powder flowability and used to classify
blend flow. The composition of each formulation and its flow characteristics are described
in Table 1. With the exception of sucrose octaacetate, all excipients employed are com-
mercial excipient grades meeting the excipient monograph listed in the USP-NF. Sucrose
octaacetate was included to mimic the presence of a drug substance which would inhibit
blend flowability. It was included in the fair flow blend at a concentration of 20% w/w and
in the passable flow blend at a concentration of 40% w/w. Formulation 1 was designed
to exhibit good flow, formulation 2 to achieve fair flow, and formulation 3 to achieve
passable flow.
Table 1. Composition of placebo direct compression blends used to develop the process model and
their flow properties.
Placebo Blend Composition (% w/w)





Microcrystalline Cellulose Diluent 48.5 38.5 28.5
Lactose Diluent 48.5 38.5 28.5
Sucrose Octaacetate Anti-flow agent 0 20 40
Crospovidone Disintegrant 1 1 1
Colloidal Silicon dioxide Flow aid 1 1 1
Magnesium Stearate Lubricant 1 1 1
Carr’s Compressibility Index 11.54 18.70 23.57
Hausner Ratio 1.13 1.23 1.31
Angle of repose (0) 27.16 37.75 43.56
Permeability at 15 kPa 109.32 54.66 21.33
2.2. Formulation Preparation
Total weight of each blend prepared was approx. 75 kg. Excipients were dispensed
according to the formulation type (Table 1) and passed through a 450 µm sieve (Sweco
Europe S.A., Nivelles, Belgium) to remove agglomerates. With the exception of magnesium
stearate, all excipients were added into a 100 L IBC (Intermediate Bulk Container, Coleshill,
UK) which was attached to the drive of the Blender unit (Pharmatech, Coleshill, UK) via a
clamping system. The IBC was rotated for 18 min at 20 rpm, for a total of 360 revolutions.
Magnesium stearate was then added to the other components in the IBC and blended for
an additional 3 min at 20 rpm, for a total of 60 revolutions.
2.3. Tablet Blend Permeability
Permeability of each formulation blend was measured using a Freeman FT4 Powder
Rheometer (Freeman Technology Ltd., Tewkesbury, UK). Blend samples were poured into a
25 mm-diameter (10 mL) splitting cylindrical vessel. A 23.5 mm helical blade was inserted
and rotated in the powder bed to condition the powder, removing excess air. Following
conditioning, the vessel was split, and the mass recorded. Permeability, k, was measured as
pressure drop across powder beds against a varying applied normal pressure (1–15 kPa),
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while the air velocity through the powder bed was maintained at constant rate of 2 mm/s.
The greater the pressure drop, the less permeable the powder. Permeability was derived





where k is the permeability (cm2), q is the flow rate of air (cm/s), µ is the viscosity of air
(Pa·s), L is the length of the powder bed (cm), and ∆P represents the pressure drop across
the powder bed (mbar).
2.4. Tablet Production
Tablets of each formulation blend were produced on one pilot-scale rotary tablet press
(KG RoTab (KG-Pharma, Scharbeutz, Germany)) and two production-scale rotary tablet
presses (Fette 1200i (Fette Compacting, Schwarzenbek, Germany) and ModulTM P (GEA,
Bergensesteenweg, Belgium)). Some key technical differences between the tablet presses
selected, including tooling details, relevant to this study are listed in Table S1. KG RoTab
and Fette 1200i were operated using main compression force control, i.e., a specified range
was set for the main compression force and if it deviated outside this specified range, the
tablet filling depth was adjusted accordingly. Module P tablet press was operated in mode 2,
which involves weight control, by measuring punch displacement during precompression.
Tablet blends were compressed using shield-shape punches to a target weight of
240 mg. A constant pre-compression force of 1 kN was used on all tablet presses. The main
compression force was optimised from the compression profile of each formulation on
each tablet press to achieve a nominal target porosity of approx. 15%. To achieve the target
porosity for different formulations, different compression forces were used. This data is
included in supplemental data, Table S2. Feeder and press speed were key press process
parameters investigated in this study and varied across runs based on the design of the
experiments described in Section 2.5.
2.5. Design of Experiments
A 12-run full response surface design with 4 centre points (23 factorial DoE) was
used to study each formulation, on each tablet press. Overall, 12 × 3 × 3 runs were
completed (108 runs). The design of experiments (DoE) was carried out using JMP statistical
software (Version 13, SAS Institute, Inc., Cary, NC, USA). The cube plot and DoE run
order of experiments for three different formulations on three tablet presses is shown in
supplementary information (Figure S1 and Table S3). The objective of the DoEs was to
identify optimum feeder speed and press speed combinations for each blend on each tablet
press design to inform the achievable production rates which produced a tablet weight
variability <1% RSD. The feeder speed rates investigated were equivalent for each press, as
shown in Table 2. However, it is important to note that due to differences in feeder designs
on each press, the feeding processes were not comparable.
Table 2. DoE feeder speed and tablet press speed levels and associated dwell times for each
tablet press.
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Table 2. Cont.





Tablet press speed levels varied across the tablet press models based on their respective
minimum and maximum press speeds. For each tablet press, at least one press speed level
was set to match another press based on their dwell times, as shown in Table 2.
2.6. Measurement of Tablet Weight Variability and Porosity
Approximately 3 kg of blend was compacted for each run of the DoE. Twenty tablets
were collected after every 1 kg of blend compacted, and weights were measured using a
Smart-test 50 Autotester (Pharmatron, Aesch, Switzerland). Mean tablet weight and tablet
weight variability (%RSD) were measured for every 20 tablets collected per 1kg blend
compacted. Tablet porosity was measured using equation 2:
(1 − Tablet Solid Fraction)× 100 (2)
2.7. Data Analysis
Process data (tablet press, feeder speed, press speed), mean tablet weights and tablet
weight variability from the independent DoEs executed for each formulation/press com-
binations were imported and analysed using JMP13 statistical software (SAS, Cary, NC,
USA). This data was integrated in JMP software to develop a model which combined the
continuous variables (press speed and feeder speed) with categorical variables (formulation
and press type). Tablet press speed was standardized for each tablet press by subtracting
the mean press speed from the actual press speed and dividing by the standard deviation.
The standardised press speeds were referred to as the ‘Coded’ press speeds. All continuous
factors were centred during the analysis. A full factorial model considering linear, 2-way,
3-way, 4-way interactions and quadratic terms was created using fit model analysis in JMP.
The model identified statistically significant factors (process parameters, formulation type
and tablet press) effecting tablet weight variability (%RSD) for the three formulations on
the three tablet presses.
3. Results
3.1. Blend Characterisation
Carr’s index, Hausner ratio, angle of repose and permeability analysis were performed
on tablet blend formulations to confirm differences in flow behaviour prior to compaction
and to classify blends. Formulation 1 exhibited the best flow characteristics, with the
lowest Carr’s index, Hausner ratio and angle of repose and the highest permeability index.
Formulation 3 exhibited the poorest flow characteristics, with the highest Carr’s index,
Hausner ratio and angle of repose and the lowest permeability index. Formulation 2
showed flow characteristics between those of formulations 1 and 3 (Table 1). The various
powder flow indices distinguished differences between the three formulations. Based
on Carr’s index and Hausner ratio values, formulation 1 was categorised as good flow.
Formulations 2 and 3 were categorised as fair- flow and passable- flow, respectively, based
on Carr’s index, Hausner ratio and angle of repose values (USP, <1174> Powder Flow).
3.2. Tablet Weight Variability (%RSD)
The influence of feeder speed and press speed on tablet weight variability (%RSD) for
formulation 1 “good flow” across three tablet presses is shown in Figure 1A. Good control
of tablet weight variability can be observed across all three tablet presses, with the Modul
P showing the lowest tablet weight %RSD across different feeder speeds and press speeds
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(Figure 1A). The exception to the trend can be seen for the combination of lower feeder
speed and higher press speed on the Fette 1200i. At these process settings, a large increase
in tablet weight variability was measured. It was also noted that for this setting, there was
a reduction in average tablet weights (221.1 ± 2.84 mg) and failure to achieve the target
tablet weight of 240 ± 18 mg. At all other settings, the target weight specification was
achieved for this formulation. The high tablet weight variability was attributed to starving
of dies at the lower feeder speed and high press speed, which was not sufficient to feed
enough material into the dies reproducibly.
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Figure 1. Plot of tablet weight variability (%RSD) for three formulations compacted on three tablet
presses. (A) Good-flow formulation, (B) Medium/fair-flow formulation and (C) Passable-flow
formulation. Each point on the graph s gnifies % RSD for n = 20 tablets. Approximately 12,000 tablets
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were compacted for individual runs in a DoE. A total of three in-process checks (IPCs) were performed
for 20 tablets after every 4000 tablets compacted, within an individual DoE run. Data point for good
flow formulation on Fette 1200i at 20 rpm feeder speed/140,000 TPH press speed was excluded in
process model development.
The effect of feeder speed and press speed on the tablet weight variability (%RSD) of
formulation 2 ‘fair flow’ is shown in Figure 1B. Across all three tablet presses, an increase
in tablet weight variability was observed at the lower feeder speed setting, with increase
in tablet press speed from lowest to highest. This trend was more pronounced on Modul
P tablet press. Across all presses, the average %RSD exceeded the nominal acceptable
commercial limits of 1% for runs at the highest press speeds. Formulation 3 “passable
flow” exhibited the highest tablet weight variability (%RSD) of the three blends on all three
presses (Figure 1C). Greatest variability was measured on the pilot-scale KG RoTab press.
Variability was greatest at the highest press speed on all three presses.
3.3. Process Model to Predict Tablet Weight Variability (%RSD)
A full factorial model was investigated to identify the significant effects of all fac-
tors and their interactions (linear, 2-way, 3-way, 4-way interactions and quadratic) on
tablet weight variability (%RSD). The fit model analysis predicted the best fit for the log-
transformation of weight variability. The full factorial model obtained was statistically
significant (p < 0.0001), with R2 of 0.8619 and low root-mean-square error. A reduced
model was fit by reducing terms to factors with a p-value less than 0.05; non-significant
factors were removed. A summary of the statistical parameters for the reduced regression
model is shown in Table 3. Effect analysis for log-transformed tablet weight variability
(%RSD) is shown in Table 4. Tablet press, formulation type, feeder speed and press speed
showed critical effects on tablet weight variability.




Root Mean Square Error 0.2779
Predicted R2 0.8277
Table 4. Effect test summary of model terms (factors) and their interactions showing significant
effects (p < 0.05) on the log-transformed tablet weight variability (%RSD).





Tablet Press*Formulation Type <0.0001
Press Speed*Press Speed <0.0001
Formulation Type*Feeder Speed*Press Speed <0.0001
Tablet Press*Feeder Speed*Press Speed 0.0035
Tablet Press*Formulation Type*Press Speed 0.0076
Formulation Type*Press Speed 0.0165
Feeder Speed*Feeder Speed 0.0481
* indicates interaction between the factors.
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It is not surprising that the four factors studied were significant individually, as they
were selected because they are widely reported and known for their impact on weight
variability. The summary of individual factors and their effects on weight variability
is shown in supplementary information, Figure S2. An interactive prediction profiler
was generated based on the model developed, to understand the effect of process factors
on weight variability. An example of the prediction profiler is shown in supplementary
information, Figure S3.
3.4. Process Optimization for Tablet Weight Variability (%RSD)
The reduced model obtained was used to establish optimum process parameters for
acceptable weight variability (%RSD). The optimum process parameters were established
to achieve a target % RSD between 0% and 1% for each formulation on each tablet press.
Figure 2 shows the contour or sweet-spot profile for formulation 1 ‘good flow’, where
the regions uncoloured indicate the optimum process conditions to achieve ≤1% RSD. At
higher tablet press speeds, higher feeder speeds were required to attain reduced tablet
weight variability for both production presses (Fette and Modul P), Figure 2B,C. The
maximum press speed at which ≤1% RSD tablet weight variability could be attained on
the pilot-scale press (KG RoTab) was 17,800 TPH (coded press speed 1) (Figure 2A).
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Formulation 1 ‘good flow’ and formulation 2 ‘fair flow’ displayed similar trends in
tablet weight variability on the KG RoTab and Fette presses (Figure 2A,B and Figure 3A,B).
Maximum tablet press speeds of 140,000 TPH could be achieved on the Fette press at
high feeder speeds. The maximum tablet press speed predicted to achieve ≤1% RSD was
93,300 TPH (coded press speed 0.01) on the Modul P (Figure 3C).
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The sweet spot for formulation 3 ‘passable flow’ on each tablet press is shown in
Figure 4. The process model did not predict that tablets weight variability ≤1% RSD could
be produced on the KG RoTab (Figure 4A). Despite this formulation possessing the poorest
flow characteristics amongst the three formulations, tablet weight variability ≤1% RSD
was predicted for the Fette at press speed of less than 102,100 TPH with gradual increase
in feeder speed from 23 rpm (Figure 4B). The sweet spot for the Modul P for formulation
3 showed that tablets with the target of ≤1% RSD were only achievable when the tablet
press was run at lower press speed of 63,600 TPH (coded press speed of −0.88) and feeder
speed of above 75 rpm (Figure 4C).
3.5. Model Validation
The process model was validated using retrospective compression data available
for two formulations, i.e., a placebo formulation and an active tablet formulation. The
active commercial formulation contained a combination of two different APIs. Firstly,
the formulation flow behavior was benchmarked to the formulations used to develop
the model. For this purpose, the permeability index was selected as the reference flow
parameter, as it plays an important role in filling of materials in the die before compression
as well as in compression packing efficiency [32]. The permeability of the formulations
was measured as described in Section 2.3, and the results are shown in Table 5. Both
formulations were classified as ‘fair flow’ due to the proximity of the measurements to the
‘fair-flow’ formulation used to establish the model (Table 5).
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from the actual pre s speed an i i i t r deviation. Refer to sup lementary information (Table S4) for the
actual press peeds.
Table 5. Permeability values for validation formulations, validation process settings, process model, actual tablet weight
variability (%RSD) for validation formulations and predicted tablet weight variability (%RSD) values calculated by the




















Fette 1200i 60,000 20 0.74 0.84 −0.1
Fette 1200i 90,000 30 1.50 1.09 0.4
Fette 1200i 120,000 40 1.21 1.46 −0.25
Active
Formulation 53.14
GEA Modul P 80,000 15 0.90 1.16 −0.26
Fette 1200i 50,000 15 0.65 0.80 −0.15
Retrospective data for these formulati ns produced on Fette 1200i and Modul P
tablet presses at defined setting were compared to values predicted using the model for
formulation 2 ‘fair flow’. The predicted and actual measured mean-weight RSD values
are r ported in Table 5. Overall, the model overestimated the tablet weight %RS . The
overestimation of the model may be due to differences in die filling behaviour between
the placebo formulation, formulation 2 “fair flow”, validation formulations. However, an
exception was observed for the placebo formulation at a tablet press speed of 90,000 TPH
and a feeder speed of 30rpm (Table 5).
A possible explanation for the underestimation for this formulation at this setting may
be a lack of sensitivity of the model to differences in blend flow behaviour at settings where
blend flow into dies can be involved, e.g., combinations of relatively high press speed and
low feeder speed. In this study, due to the unavailability of a comprehensive set of flow
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data for the retrospective blends used for validation, a single parameter, permeability, was
used. Other parameters commonly employed to describe flow and electrostatics, suction
fill behavior and environmental conditions (humidity), or combinations of parameters
might better identify critical flow characteristics when benchmarking blends into categories
for the model.
4. Discussion
The study presented demonstrates the development of a process model to predict
tablet weight variability, expressed as %RSD, for direct compression formulations with
varying flow properties, across pilot- and production-scale tablet presses. Similar to an
earlier study by Razavi et al. (2020), the logarithm of %RSD was chosen as the response
variable. The process model included linear, quadratic and interaction effects of input
parameters on log(%RSD), R2adj of 84.82% and R
2
pred of 82.77%. The approach undertaken
incorporated the tablet press model and formulation flow as categorical variables in the
experimental design and feeder and press speed as numerical variables. The resulting
model and formulation–tablet press-specific optimum process conditions provided a com-
prehensive overview of the behaviour of direct compression formulations with varying
flow behaviour across a range of press types. The modelling approach used advances
the conventional QbD approach, where process-related models and desired processing
parameters are generally limited to a single tablet press model [33].
Earlier studies have focused on the effect of feeder design and tablet press control
strategy on tablet weight variability and optimise designs to reduce tablet weight variabil-
ity [20,33]. The objective of this study was not to compare the capability of different tablet
press designs but to develop a modelling approach to predict how formulations would
behave on tablet presses with standard feeder systems and control strategies employed
routinely in an industrial setting. The modelling approach undertaken enables a company
to predict tablet weight variability across tablet presses in their inventory for formulations
with varying flow. While this study investigated three specific tablet press models, the
approach taken is applicable to other tablet press designs or set-ups. For example, in this
study the weight control strategy employed for Module P was mode 2 (pre-compression
displacement at equal force). The model could be developed or expanded to include
other weight control mechanisms on the Modul P such as mode 5 (main compression
force measurement).
The model was developed with placebo formulations designed to exhibit different
flow characteristics. Blend flow behaviour was classified categorically using established
Carr’s index, Hausner ratio, angle of repose values [34]. The predictive capability of the
model was validated using process and tablet weight data from active and placebo direct-
compression formulations related to previous production-scale tablet press models. Blend
permeability measurements were used to benchmark the validation blends to blend flow
categories used in the model. Blend permeability was selected, as it was identified, together
with compressibility, density, flowability, porosity and wall friction angle, as the most
critical parameter related to die filling in a recent study by [11]. Overall validation showed
the model has a low negative bias, shown in its predicted tablet weight variability for both
tablet press models at the majority of settings investigated. This may be attributed to the
shorter DoE run times that predicted higher weight variability, compared to data from
validation formulation runs recorded after attaining steady state, which has a greater run
time. However, for one formulation/press setting, the model showed a low positive bias.
Understanding of the model’s prediction capability may be improved by using more blend
characteristics to benchmark validation formulations to formulations employed in model
development. The incorporation of additional blend characteristics to describe blend flow
could elucidate further differences between blend die filling behaviours.
When applied in an industrial setting, the process modelling approach undertaken
offers several benefits. During development, the model can be applied to predict possible
production speeds following scale-up based on formulation flow behaviour measured
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during formulation development. Depending on the API loading requirements, it may be
possible to reformulate the blend to improve formulation flow and thereby increase com-
mercial production speeds. It is also interesting to note from the results of this study that it
was not possible to achieve ≤1% RSD for formulation 3 ‘passable flow’ on the pilot-scale
KG RoTab press which is used to develop formulations. However, when compacting this
formulation on the production-scale Fette press, it was possible to produce tablets with
≤ % RSD at speeds as high as 100,000 TPH. The application of the model to understand
differences in die filling behaviour, measured as tablet weight variability, between a devel-
opment and a production-scale press can provide reassurance during process development
that a formulation with ‘passable flow’ can be produced at production scale, despite not
meeting the desirable specifications of tablet weight variability when produced at pilot
scale. During commercial production, understanding differences in die filling behaviour
between production-scale presses facilitates the selection of optimum feeder and press
speed to suit formulation flow when transferring between presses. It can be also used to
select a tablet press from an available inventory to maximise tablet production. Finally,
the process modelling approach developed can streamline tech transfer activities between
lab-scale and production-scale tablet presses. Utilising this approach has the potential to
reduce process development time and thus bring new products to the market faster.
5. Conclusions
An empirical process model was developed to predict tablet weight variability, ex-
pressed as percentage relative standard deviation, for direct compression formulations with
varying flow properties, across pilot- and production-scale tablet presses. The model was
developed using a DoE approach, with press and feeder speed as numerical variables and
press type and formulation type as categorical variables. Optimum processing conditions
were established for each formulation, good, fair and passable flow, on each press to achieve
tablet weight variability ≤1% RSD. The model developed was successfully validated using
a placebo and an active formulation on two production presses. Blend permeability was
used to benchmark validation formulations to model formulation categories. This allows
the prediction of commercial-scale tablet weight control based on small-scale blend data
during early-stage development. The modelling approach undertaken can be applied to an
industrial setting to aid formulation development, scale-up and transfer of formulations
between production presses.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13071033/s1, Figure S1: Full response surface design DoE with 8 runs (green)
and 4 centre points (blue). Figure S2: Effect summary of model terms (factors) and their interactions
showing significant effects on the log transformed tablet weight variability (%RSD). Figure S3:
Prediction profiler showing weight RSD as response (A). Medium flow formulation on Fette 1200i
at coded press speed of −0.609 (60,000 TPH). (B) Passable flow formulation on Modul P at coded
press speed of 0 (93,000T PH). Details shown in red font indicate input factors in the model and
output responses. Profiles indicate the change in response as individual factors are altered. Table S1:
Key technical specification of tablet press in this study with specific type of tooling. Table S2: Pre-
compression force and main compression force applied to achieve the target tablet porosity of 15%
for each formulation on each tablet press. Table S3: DoE run order of experiments for three different
formulations on three tablet presses. The center points are shown in bold. Table S4: Actual tablet
press speeds.
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